← All companies

TRAX

First Tracks Biotherapeutics, Inc.

TRAX Nasdaq Pharmaceutical Preparations EDGAR ↗

$46.16

-1.62 -3.39%

Key statistics

from XBRL data in SEC filings

Market cap

$1.61B

Revenue (TTM)

—

Net income (TTM)

—

EPS (TTM)

—

P/E ratio

—

Dividend yield

—

Free cash flow

—

Cash

$248M

Total assets

$291M

Gross margin

—

52-week range

$14.72 – $48.00

Recent SEC filings

40 most recent

Annual, quarterly & current reports

8-K Entered a material agreement Jun 22, 2026 10-Q Quarter ended 2026-03-31 May 14, 2026 8-K Results of operations (earnings release) May 14, 2026 8-K Entered a material agreement; Completed an acquisition or disposition; Unregistered sale of equity; Modified rights of security holders; Change in control; Director or officer change; Amended charter or bylaws; Other events Apr 20, 2026 8-K Regulation FD disclosure Apr 3, 2026

Other filings

SCHEDULE 13G Jul 28, 2026 4 Jun 17, 2026 4 Jun 17, 2026 4 Jun 17, 2026 4 Jun 17, 2026 4 Jun 17, 2026 4 Jun 17, 2026 4/A Jun 12, 2026 4/A Jun 12, 2026 4/A Jun 12, 2026 4/A Jun 12, 2026 4/A Jun 12, 2026 4/A Jun 12, 2026 424B3 May 15, 2026 424B3 May 14, 2026 4 May 14, 2026 4 May 14, 2026 4 May 14, 2026 4 May 14, 2026 4 May 14, 2026 4 May 14, 2026 4 May 14, 2026 4 May 14, 2026 4 May 14, 2026 4 May 14, 2026 EFFECT May 12, 2026 CORRESP May 8, 2026 S-1 May 8, 2026 UPLOAD May 6, 2026 DRS May 1, 2026 4 Apr 23, 2026 3 Apr 23, 2026 SCHEDULE 13G Apr 22, 2026 4 Apr 22, 2026 3 Apr 22, 2026